Results 81 to 90 of about 7,822 (173)

Oncolytic adenoviruses encoding bispecific T cell engagers or a novel trispecific T cell engager for dual-targeting of c-MET and EGFR

Molecular Therapy: Oncology
This study reports a strategy to overcome immune escape of tumors during viro-immunotherapy due to tumor heterogeneity. We pursued a dual-targeting approach of epidermal growth factor receptor (EGFR) and cellular mesenchymal epithelial transition factor (
Martin A. Boos, Oliver Seifert, Stefanie Sawall, Jessica Genz, Annika Huber, Ilse Hofmann, Roland E. Kontermann, Guy Ungerechts, Dirk M. Nettelbeck   +8 more
doaj   +1 more source

The combination therapy of oncolytic virotherapy

Frontiers in Pharmacology
Introduction: Compared to other cancer immunotherapies, oncolytic viruses possess several advantages, including high killing efficiency, excellent targeting capabilities, minimal adverse reactions, and multiple pathways for tumor destruction. However, the efficacy of oncolytic viruses as a monotherapy often falls short of expectations.
Yue Wang, Mengying Zhu, Mengying Zhu, Huanyu Chi, Huanyu Chi, Yang Liu, Guilin Yu   +6 more
openaire   +3 more sources

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Oncolytic virotherapy: the questions and the promise

Oncolytic Virotherapy, 2013
Oncolytic virotherapy is a new strategy to reduce tumor burden through selective virus replication in rapidly proliferating cells. Oncolytic viruses are members of at least ten virus families, each with its advantages and disadvantages. Here, I briefly review the recent advances and key challenges, as exemplified by the best-studied platforms.
openaire   +3 more sources

Current Development of Virotherapy in Breast Cancer: A Brief Review

Acta Medica Bulgarica
Breast cancer is the cancer with the greatest incidence in the world by 2020. This cancer has a high mortality rate, has the capability of metastasizing, and causes damage to important organs of the human body.
Sasmana I., Putri P., Dewi N., Supadmanaba I., Wihandani D.   +4 more
doaj   +1 more source

Intratumoral oncolytic virotherapy in pancreatic cancer: from feasibility to immune priming. [PDF]

Transl Gastroenterol Hepatol
Nishida T, Hayashi Y.
europepmc   +1 more source

Emerging Oncolytic Viruses: Beyond Adenoviruses and Herpes Simplex Virus. [PDF]

J Cancer
Chokkakula S, Yin C, Yang B, Chong S, Pathakumari B, Zhang YQ, Nirmala PV, Lai KW, Naveen B, Tang Q.   +9 more
europepmc   +1 more source

Enhancing oncolytic reovirus therapy with proteasome inhibitors in multiple myeloma. [PDF]

Ann Med Surg (Lond)
Aleem MR, Baloch K, Shahid M, Talha SS.
europepmc   +1 more source

Engineering systemic oncolytic virotherapy through immune-compatible delivery and programmable tumor cell death. [PDF]

Mol Ther Oncol
Chen X, Chen Y, Ping Y.
europepmc   +1 more source

Reprogramming the immune orchestra for glioblastoma: oncolytic viruses and the B-cell connection. [PDF]

Cell Mol Immunol
Dieli C, Di Simone M, Dieli F, Meraviglia S.   +3 more
europepmc   +1 more source